CHOP Program Gives Kids a New Lease on Life, With Their Own Hearts

PHILADELPHIA, PA – February 04, 2026 – A groundbreaking new approach at Children's Hospital of Philadelphia (CHOP) is transforming the landscape of pediatric heart failure, offering a chance for the sickest children to heal their own hearts and avoid a transplant. Researchers at the hospital's distinguished Cardiac Center have pioneered a standardized program that uses ventricular assist devices (VADs)—mechanical pumps that support a failing heart—not just as a temporary bridge to transplantation, but as an active tool for recovery.

Published in the Journal of the American Heart Association, the study details a remarkable success rate: 26% of pediatric patients on VADs in the program were able to have the devices removed after their hearts recovered enough function to work independently. The findings represent a significant paradigm shift, offering new hope to families and challenging long-held conventions in pediatric cardiology.

A New Paradigm: From Bridge to Recovery

For decades, VADs have served as a life-saving but temporary measure for children with severe heart failure. These powerful pumps take over the heart's workload, allowing a child to regain strength, grow, and wait for a suitable donor heart to become available. The use of these devices has surged, with over 1,400 placed in more than 1,200 children across the United States between 2018 and 2023. While indispensable, the ultimate goal has almost always been a heart transplant.

CHOP's new program reframes this entire approach. "It suggests there may be higher than anticipated rates of heart recovery in children with cardiomyopathy who are supported by VADs and introduces a novel paradigm in which VADs can be thought of as tools for recovery rather than just bridges to heart transplant," said Dr. Jonathan Edelson, the study's senior author and Medical Director of the Heart Transplant and Ventricular Assist Device Program at CHOP.

This shift is crucial. A heart transplant, while life-saving, involves a lifetime of powerful immunosuppressant drugs to prevent organ rejection, carrying risks of infection, kidney damage, and other complications. Furthermore, the number of available donor hearts for children is critically limited. By fostering native heart recovery, the CHOP program offers a path that can potentially bypass these challenges altogether, improving a child's long-term quality of life.

Inside the Groundbreaking Program

Recognizing the potential for the heart to heal, a multidisciplinary team at CHOP formally implemented its specialized ventricular recovery program in 2022. The protocol is built on four core pillars designed to systematically identify and promote recovery:

1. Universal Assessment: Every child on a VAD is considered a potential candidate for recovery and device removal.
2. Aggressive Medication: All patients receive a universal regimen of reverse remodeling medications, drugs that help the heart muscle heal and regain strength.
3. Stepwise Evaluation: Patients undergo a rigorous, stepwise evaluation process using echocardiography, exercise testing, and cardiac catheterization to carefully measure improvements in heart function.
4. Multidisciplinary Collaboration: A team of surgeons, cardiologists, nurses, and other specialists meets regularly to discuss each patient's progress and make collective decisions.

Over the two-year study period, this approach was applied to 35 patients supported by durable VADs for conditions ranging from cardiomyopathy to congenital heart disease. The results were striking. Nine children recovered enough to have their devices explanted. In the short term, eight of the nine are thriving at home without the device. The ninth patient was ultimately listed for a transplant, received a new heart, and is also home and doing well.

Researchers noted that most recoveries occurred in infants, suggesting that younger hearts may be more adaptable or that a shorter duration of heart failure before VAD implantation could be a key factor. The consistent use of heart failure medications across all recovered patients also points to a promising area for future research.

Putting the Breakthrough in Context

CHOP's reported 26% recovery rate stands in stark contrast to previously published data. Broader registry studies and meta-analyses from recent years have shown myocardial recovery rates in pediatric VAD patients ranging from just 3% to about 12%. The success of CHOP's formalized protocol suggests that a dedicated, systematic approach may be the key to unlocking the heart's hidden potential for healing.

While the concept of a "bridge to recovery" is known at other top pediatric cardiac centers, CHOP's work is significant for being a dedicated, programmatic effort with a high, published success rate. It provides a potential roadmap for other institutions to follow, transforming an occasional, fortunate outcome into a deliberate therapeutic goal.

This is particularly important given the stakes. For families, the journey with a VAD is one of mixed emotions. The device can bring a child back from the brink, allowing them to leave the intensive care unit and even return home. However, it also means being tethered to equipment, managing complex medication regimens, and living with the constant anxiety of a potential transplant.

The prospect of avoiding that transplant is life-altering. "For some families, opting for heart function recovery and device removal is preferable over a heart transplant, despite inherent risks," Dr. Edelson noted.

The Path Forward

The immediate success of the program raises important questions for the future. Chief among them is the long-term durability of the recovery. While short-term outcomes are excellent, with no deaths or device re-implantations in the recovered group, researchers acknowledge that more time is needed to understand how these children will fare years down the road. The risk of heart failure recurrence exists, and ongoing, careful monitoring will be essential.

Nevertheless, the research marks a pivotal moment. It underscores the necessity of ongoing evaluation and careful patient selection to maximize the chances of recovery. By proving that a structured approach can yield such profound results, the CHOP team has not only offered a new future for its own patients but has also lit a path for the entire field of pediatric cardiology. This innovative work champions a future where the primary goal is not just to replace a failing heart, but to give a child their own heart back.